Medtronic has received the US Food and Drug Administration (FDA) approval for its Talent Thoracic Stent Graft with Captivia Delivery System, used in the endovascular repair of thoracic aortic aneurysms (TAA).
The Talent Captivia System is indicated for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy.
The Talent Captivia System features a tip capture mechanism for controlled deployment and precise placement of the implantable medical device and also a hydrophilic coating to ease insertion into the femoral artery and navigation through the iliac arteries (around the pelvis) en route to the aorta.
The Talent Captivia System is inserted into the femoral artery in the patient’s groin and moved up through blood vessels to the aorta during thoracic endovascular aortic repair (TEVAR).
The system helps the physicians to expand the stent graft within the aorta, creating a new path for blood flow that reduces pressure on the bulge and the risk of rupture.
Medtronic offers the Talent Thoracic Stent Graft in longer lengths up to 215mm, to accommodate the aortic anatomies of more patients.
Medtronic Endovascular Innovations business vice president and general manager Tony Semedo said that FDA approval of the Talent Captivia System builds on this legacy of leadership in the field of endovascular aortic repair.